Welcome to LookChem.com Sign In|Join Free
  • or
3,4,6,7,8,9-hexahydropyrido[3,4-b]indolizin-1(2H)-one is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1346672-96-5

Post Buying Request

1346672-96-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1346672-96-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1346672-96-5 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,4,6,6,7 and 2 respectively; the second part has 2 digits, 9 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1346672-96:
(9*1)+(8*3)+(7*4)+(6*6)+(5*6)+(4*7)+(3*2)+(2*9)+(1*6)=185
185 % 10 = 5
So 1346672-96-5 is a valid CAS Registry Number.

1346672-96-5Relevant academic research and scientific papers

Single-Step Synthesis of 5,6,7,8-Tetrahydroindolizines via Annulation of 2-Formylpiperidine and 1,3-Dicarbonyl Compounds

Capomolla, Simona S.,Lim, Ngiap-Kie,Zhang, Haiming

, p. 3564 - 3567 (2015)

An expedient single-step synthesis of 5,6,7,8-tetrahydroindolizines has been achieved via the annulation of commercially available 2-formylpiperidine hydrochloride and 1,3-dicarbonyl compounds in THF in the presence of pyrrolidine and 4 ? molecular sieves

A fit for purpose synthesis of Bruton's tyrosine kinase inhibitor GDC-0852

Lim, Ngiap-Kie,Zhang, Haiming,Sowell, C. Gregory,Gosselin, Francis

, (2020/10/02)

The development of an expedient synthesis to GDC-0852 (1), a reversible BTK inhibitor drug candidate, is described. The key starting material tricyclic lactam 5 was prepared by an annulation reaction of unprotected piperidine-2-carbaldehyde HCl salt (20) and N-Boc piperidine-2,4-dione 21 in a safe and scalable manner. A highly selective Pd-catalyzed C[sbnd]N coupling of lactam 5 and linker 2a, followed by Suzuki?Miyaura coupling to fragment 8 subsequently provided a direct and convergent access to the penultimate 17. A simple NaBH4 aldehyde reduction completed the synthesis to GDC-0852 (1) in high yield (54% over 3 steps from 5) and purity (99.0 A% HPLC).

HETEROARYL PYRIDONE AND AZA-PYRIDONE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY

-

, (2015/11/16)

Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X, X, and Xare N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I foranddiagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BICYCLIC PIPERAZINE COMPOUNDS

-

, (2013/05/21)

Bicyclic piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

ALKYLATED PIPERAZINE COMPOUNDS

-

, (2013/05/21)

Alkylated piperazine compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRIDONE AND AZA-PYRIDONE COMPOUNDS AND METHODS OF USE

-

Page/Page column 111; 165, (2011/11/30)

Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1346672-96-5